SEARCH

SEARCH BY CITATION

References

  • Abe H, Takeshita T, Nagata K, Arita T, Endo Y, Fujita Tet al. (1999). Molecular cloning, chromosome mapping and characterization of the mouse CRTH2 gene, a putative member of the leukocyte chemoattractant receptor family. Gene 227: 7177.
  • Alexander SPH, Mathie A, Peters JA (2011). Guide to Receptors and Channels (GRAC), 5th Edition. Br J Phamacol 164 (Suppl. 1): S1S324.
  • Angeli V, Staumont D, Charbonnier AS, Hammad H, Gosset P, Pichavant Met al. (2004). Activation of the D prostanoid receptor 1 regulates immune and skin allergic responses. J Immunol 172: 38223829.
  • Anhut H, Peskar BA, Bernauer W (1978). Release of 15-keto-13,14-dihydro-thromboxane B2 and prostaglandin D 2 during anaphylaxis as measured by radioimmunoassay. Naunyn Schmiedebergs Arch Pharmacol 305: 247252.
  • Arimura A (2010). Discovery of a First-in-Class Drug, a Prostaglandin D2 Antagonist, for the Treatment of Allergic Diseases. Molecular Imaging for Integrated Medical Therapy and Drug Development Part IV, pp. 281287.
  • Balzar S, Fajt ML, Comhair SA, Erzurum SC, Bleecker E, Busse WWet al. (2011). Mast cell phenotype, location and activation in severe asthma, data from the Severe Asthma Research Program. Am J Respir Crit Care Med 183: 299309.
  • Banfield C, Parnes J, Emery M, Ni L, Zhang N, Hodsman P (2010). Single-dose, first-in-human study of AMG 853: pharmacokinetics, pharmacodynamics, and safety in healthy adults. Am J Respir Crit Care Med 181: A5397.
  • Barnes N, Pavord I, Chuchalin A, Bell J, Hunter M, Lewis Tet al. (2012). A randomised, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma. Clin Exp Allergy 42: 3848.
  • Barski OA, Tipparaju SM, Bhatnagar A (2008). The aldo-keto reductase superfamily and its role in drug metabolism and detoxification. Drug Metab Rev 40: 553624.
  • Birkinshaw TN, Teague SJ, Beech C, Bonnert RV, Hill S, Patel Aet al. (2006). Discovery of potent DP2 (DP2) receptor antagonists. Bioorg Med Chem Lett 16: 42874290.
  • Black JW, Leff P (1983). Operational models of pharmacological agonism. Proc Royal Soc Biol 84: 141162.
  • Bonnert R, Rasul R (2004). Preparation of 3-(hetero)arylthio-indoleacetic acids as DP2 receptor ligands for the treatment of respiratory disorders. PCT Int Appl WO2004106302.
  • Carrillo J, Weyman-Jones C, Beri R, Jupp R, Arrowsmith E, McNicol Get al. (2005). Pharmacological characterisation of dog recombinant DP2. Br J Pharmacol 3: 102P.
  • Chaudhry PS, Cabrera J, Juliani HR, Varma SD (1983). Inhibition of human lens aldose reductase by flavonoids, sulindac and indomethacin. Biochem Pharmacol 32: 19951998.
  • Cheng Y-C, Prusoff WH (1973). Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22: 30993108.
  • Chevalier E, Stock J, Fisher T, Dupont M, Fric M, Fargeau Het al. (2005). Cutting edge: chemoattractant receptor-homologous molecule expressed on Th2 cells plays a restricting role on IL-5 production and eosinophil recruitment. J Immunol 175: 20562060.
  • Crea AE, Nakhosteen JA, Lee TH (1992). Mediator concentrations in bronchoalveolar lavage fluid of patients with mild asymptomatic bronchial asthma. Eur Respir J 5: 190195.
  • Foster PS (1999). Allergic networks regulating eosinophilia. Am J Respir Cell Mol Biol 21: 451454.
  • Gervais FG, Cruz RP, Chateauneuf A, Gale S, Sawyer N, Nantel Fet al. (2001). Selective modulation of chemokinesis, degranulation, and apoptosis in eosinophils through the PGD2 receptors CRTH2 and DP. J Allergy Clin Immunol 108: 982988.
  • Gervais FG, Sawyer N, Stocco R, Hamel M, Krawczyk C, Sillaots Set al. (2011). Pharmacological characterization of MK-7246, a potent and selective CRTH2 (chemoattractant receptor-homologous molecule expressed on T-helper type 2 cells) antagonist. Mol Pharmacol 79: 6976.
  • Gyles SL, Xue L, Townsend ER, Wettey F, Pettipher R (2006). A dominant role for chemoattractant receptor-homologous molecule expressed on T helper type 2 (Th2) cells (CRTH2) in mediating chemotaxis of CRTH2+ CD4+ Th2 lymphocytes in response to mast cell supernatants. Immunology 119: 362368.
  • Heinemann A, Schuligoi R, Sabroe I, Hartnell A, Peskar BA (2003). Delta 12-prostaglandin J2, a plasma metabolite of prostaglandin D2, causes eosinophil mobilization from the bone marrow and primes eosinophils for chemotaxis. J Immunol 170: 47524758.
  • Hirai H, Tanaka K, Yoshie O, Ogawa K, Kenmotsu K, Takamori Yet al. (2001). Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils and basophils via seven-transmembrane receptor DP2. J Exp Med 193: 255261.
  • Hirai H, Tanaka K, Takano S, Ichimasa M, Nakamura M, Nagata K (2002). Agonistic effect of indomethacin on a prostaglandin D2 receptor, CRTH2. J Immunol 168: 981985.
  • Horak F, Toth J, Hirschwehr R, Marks B, Stubner UP, Jager Set al. (1998). Effect of continuous allergen challenge on clinical symptoms and mediator release in dust-mite-allergic patients. Allergy 53: 6872.
  • Jin Y, Penning TM (2007). Aldo-keto reductases and bioactivation/detoxication. Annu Rev Pharmacol Toxicol 47: 263292.
  • Kenakin TP (2009). Orthosteric drug antagonism. In: Kenakin TP (ed.). A Pharmacology Primer: Theory, Applications and Methods, 3rd edn. Elsevier Academic Press: Burlington, MA, pp. 101127.
  • Lewis RA, Soter NA, Diamond PT, Austen KF, Oates JA, Roberts LJ 2nd (1982). Prostaglandin D2 generation after activation of rat and human mast cells with anti-IgE. J Immunol 129: 16271631.
  • Liu MC, Bleecker ER, Lichtenstein LM, Kagey-Sobotka A, Niv Y, McLemore TLet al. (1990). Evidence for elevated levels of histamine, prostaglandin D2, and other bronchoconstricting prostaglandins in the airways of subjects with mild asthma. Am Rev Respir Dis 142: 126132.
  • Lukacs NW, Berlin AA, Franz-Bacon K, Sásik R, Sprague LJ, Ly TWet al. (2008). CRTH2 antagonism significantly ameliorates airway hyperreactivity and downregulates inflammation-induced genes in a mouse model of airway inflammation. Am J Physiol Lung Cell Mol Physiol 295: L767L779.
  • Luker T, Bonnert R, Brough S, Cook AR, Dickinson MR, Dougall Iet al. (2011). Substituted indole-1-acetic acids as potent and selective DP2 antagonists-discovery of AZD1981. Bioorg Med Chem Lett 21: 62886292.
  • Marshall C, Sargent C, Young S, Barker J (2005). Is there a CRTH2 functional response in the dog? Br J Pharmacol (Winter Meeting) 3: 103P. Available at: http://www.pa2online.org/abstract/abstract.jsp?abid=28258&author=Sargent&cat=-1&period=23 (accessed 6/12/12).
  • Marshall C, Sargent C, Young S, Barker J (2006). Functional effects of DP2 in the dog. Am J Respir Crit Care Med 3 (abstract issue): A584.
  • Mathiesen JM, Christopoulos A, Ulven T, Royer JF, Campillo M, Heinemann Aet al. (2006). On the mechanism of interaction of potent surmountable and insurmountable antagonists with the prostaglandin D2 receptor CRTH2. Mol Pharmacol 69: 14411453.
  • Matsuoka T, Hirata M, Tanaka H, Takahashi Y, Murata T, Kabashima Ket al. (2000). Prostaglandin D2 as a mediator of allergic asthma. Science 287: 20132017.
  • Monneret G, Gravel S, Diamond M, Rokach J, Powell WS (2001). Prostaglandin D2 is a potent chemoattractant for human eosinophils that acts via a novel DP receptor. Blood 98: 19421948.
  • Monneret G, Cossette C, Gravel S, Rokach J, Powell WS (2003). 15R-Methyl-prostaglandin D2 is a potent and selective DP2/DP2 in human eosinophils. J Pharmacol Exp Ther 304: 349355.
  • Murray JJ, Tonnel AB, Brash AR, Roberts LJ 2nd, Gosset P, Workman Ret al. (1986). Release of prostaglandin D2 into human airways during acute antigen challenge. N Engl J Med 315: 800804.
  • Nagata K, Hirai H, Tanaka K, Ogawa K, Aso T, Sugamura Ket al. (1999a). DP2, an orphan receptor of T-helper-2-cells, is expressed on basophils and eosinophils and responds to mast cell-derived factor(s). FEBS Lett 459: 195199.
  • Nagata K, Tanaka K, Ogawa K, Kemmotsu K, Imai T, Yoshie O (1999b). Selective expression of a novel surface molecule by human Th2 cells in vivo. J Immunol 162: 12781286.
  • Norman P (2010). DP2 receptor antagonists in development. Exp Opin Invest Drugs 19: 947961.
  • Nowak D, Grimminger F, Jorres R, Oldigs M, Rabe KF, Seeger Wet al. (1993). Increased LTB4 metabolites and PGD2 in BAL fluid after methacholine challenge in asthmatic subjects. Eur Respir J 6: 405412.
  • Petrash JM (2004). All in the family: aldose reductase and closely related aldo-keto reductases. Cell Mol Life Sci 61: 737749.
  • Pettipher R, Hansel TT (2008). Antagonists of the prostaglandin D2 receptor CRTH2. Drug News Perspect 21: 317322.
  • Pettipher R, Whittaker M (2012). Update on the development of antagonists of chemoattractant receptor-homologous molecule expressed on Th2 Cells (CRTH2). From lead optimization to clinical proof-of-concept in asthma and allergic rhinitis. J Med Chem 55: 29152931.
  • Philip G, van Adelsberg J, Loeys T, Liu N, Wong P, Lai Eet al. (2009). Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis. J Allergy Clin Immunol 124: 942948.
  • Royer JF, Schratl P, Carillo JJ, Jupp R, Barker J, Weyman-Jones Cet al. (2008). A novel antagonist of prostaglandin D2 blocks the locomotion of eosinophils and basophils. Eur J Clin Invest 38: 663671.
  • Sanyal S, Kuvin JT, Karas RH (2010). Niacin and laropiprant. Drugs Today (Barc) 46: 371378.
  • Satoh T, Moroi R, Aritake K, Urade Y, Kanai Y, Sumi Ket al. (2006). Prostaglandin D2 plays an essential role in chronic allergic inflammation of the skin via CRTH2 receptor. J Immunol 177: 26212629.
  • Schuligoi R, Sturm E, Luschnig P, Konya V, Philipose S, Sedej Met al. (2010). CRTH2 and d-type prostanoid receptor antagonists as novel therapeutic agents for inflammatory diseases. Pharmacology 85: 372382.
  • Singh D, Cadden P, Hunter M, Collins LP, Perkins M, Pettipher Ret al. (2012). Inhibition of the asthmatic allergen challenge response by the CRTH2 antagonist OC000459. Eur Respir J (Epub April 2012).
  • Spik I, Brénuchon C, Angéli V, Staumont D, Fleury S, Capron Met al. (2005). Activation of the prostaglandin D2 receptor DP2/CRTH2 increases allergic inflammation in mouse. J Immunol 174: 37033708.
  • Stebbins KJ, Broadhead AR, Correa LD, Scott JM, Truong YP, Stearns BAet al. (2010). Therapeutic efficacy of AM156, a novel prostanoid DP2 receptor antagonist, in murine models of allergic rhinitis and house dust mite-induced pulmonary inflammation. Eur J Pharmacol 638: 142149.
  • Stubbs VE, Schratl P, Hartnell A, Williams TJ, Peskar BA, Heinemann Aet al. (2002). Indomethacin causes prostaglandin D(2)-like and eotaxin-like selective responses in eosinophils and basophils. J Biol Chem 277: 2601226020.
  • Uller L, Mathiesen JM, Alenmyr L, Korsgren M, Ulven T, Högberg Tet al. (2007). Antagonism of the prostaglandin D2 receptor CRTH2 attenuates asthma pathology in mouse eosinophilic airway inflammation. Respir Res 8: 1625.
  • Ulven T, Kostenis E (2010). Novel CRTH2 antagonists: a review of patents from 2006 to 2009. Exp Opin Ther Patents 20: 15051530.
  • Ulven T, Receveur J-M, Grimstrup M, Rist O, Frimurer TM, Gerlach L-Oet al. (2006). Novel selective orally active CRTH2 antagonists for allergic inflammation developed from in silico derived hits. J Med Chem 49: 66386641.
  • Wenzel SE, Westcott JY, Smith HR, Larsen GL (1989). Spectrum of prostanoid release after bronchoalveolar allergen challenge in atopic asthmatics and in control groups. An alteration in the ratio of bronchoconstrictive to bronchoprotective mediators. Am Rev Respir Dis 139: 450457.
  • Xue L, Gyles SL, Wettey FR, Gazi L, Townsend E, Hunter MGet al. (2005). Prostaglandin D2 causes preferential induction of proinflammatory Th2 cytokine production through an action on chemoattractant receptor-like molecule expressed on Th2 cells. J Immunol 175: 65316536.
  • Xue L, Barrow A, Pettipher R (2009a). Interaction between prostaglandin D and chemoattractant receptor-homologous molecule expressed on Th2 cells mediates cytokine production by Th2 lymphocytes in response to activated mast cells. Clin Exp Immunol 156: 126133.
  • Xue L, Barrow A, Pettipher R (2009b). Novel function of CRTH2 in preventing apoptosis of human Th2 cells through activation of the phosphatidylinositol 3-kinase pathway. J Immunol 182: 75807586.